A widely used diabetes medicine may offer an unexpected benefit for eye health, according to a new study.
Researchers have found that people who take metformin may have a lower chance of developing a serious eye condition called neovascular age-related macular degeneration, often shortened to nAMD. This condition is one of the leading causes of vision loss in older adults.
The study was published online on January 30 in the journal Ophthalmology Retina. It adds to growing interest in how existing medicines might help prevent diseases beyond their original purpose.
Age-related macular degeneration, or AMD, is a common eye disease that mainly affects people over the age of 50. It damages the macula, which is the part of the eye responsible for sharp, central vision.
This kind of vision is needed for reading, driving, and recognizing faces. There are two main types of AMD: dry and wet. The wet form, also called neovascular AMD, is more severe and can lead to rapid vision loss.
In nAMD, abnormal blood vessels grow under the retina. These vessels can leak fluid or blood, which damages the eye and affects vision. Although treatments are available, they are often expensive, require repeated injections into the eye, and do not fully restore lost vision. Because of this, finding ways to prevent the disease is very important.
Metformin is a medicine that has been used for many years to treat type 2 diabetes. It helps control blood sugar levels and is generally considered safe, affordable, and widely available. In recent years, scientists have started to explore whether metformin may also have other health benefits, such as reducing inflammation or slowing aging processes in the body.
In this study, researchers from the University of Chicago, led by Dr. Jason F. Xiao, looked at medical data collected between 2008 and 2017.
They identified more than 22,000 people who had newly developed nAMD and compared them with a similar number of people who did not have the disease. The researchers carefully matched the two groups so they could make a fair comparison.
They also examined a subgroup of people with diabetes, since metformin is commonly used in this group. In total, over 6,600 patients with nAMD and over 5,500 people without the condition were included in this subgroup analysis.
The results showed that people who used metformin had a lower chance of developing nAMD compared to those who did not use the drug. Overall, metformin use was linked to about a 16 percent reduction in the odds of developing the condition.
The researchers also looked at how the amount of metformin taken over time affected the results. They found that the strongest association was seen in people who had taken a moderate total dose of the drug.
However, these dose-related findings were not completely clear, because the study relied on medical records and could not confirm whether patients took the medicine exactly as prescribed.
Among people with diabetes, the protective association of metformin was still present. The results suggested that metformin users in this group also had a lower chance of developing nAMD.
Interestingly, the benefit appeared stronger in patients with diabetes who did not yet have eye damage related to diabetes, known as retinopathy. In those who already had diabetic retinopathy, the protective effect was not seen.
The researchers suggest that metformin’s effects on the body may help explain these findings. The drug is known to reduce inflammation and improve how cells use energy, both of which may help protect delicate tissues in the eye. However, the exact reason why metformin may lower the risk of nAMD is still not fully understood.
It is important to note that this study shows a link between metformin use and lower risk of nAMD, but it does not prove that metformin directly prevents the disease. Other factors, such as overall health, lifestyle, or access to healthcare, may also play a role. More research, including clinical trials, will be needed to confirm these findings.
The authors also noted that two of the researchers have ties to the biopharmaceutical industry, which should be considered when interpreting the results.
Overall, this study offers promising early evidence that a common and low-cost medicine may help protect against a serious eye disease. If future research confirms these results, metformin could become an important tool in preventing vision loss in older adults, especially those at higher risk.
From a broader perspective, this study highlights an important trend in modern medicine. Researchers are increasingly looking at existing drugs to see if they can be used in new ways.
This approach can save time and cost compared to developing new drugs from scratch. However, it also requires careful testing to make sure the benefits are real and that the treatment is safe for new uses.
In conclusion, while metformin is already well known for treating diabetes, it may also have a role in protecting eye health. This is an exciting possibility, but more studies are needed before doctors can recommend it specifically for preventing macular degeneration.
If you care about diabetes, please read studies about bananas and diabetes, and honey could help control blood sugar.
For more health information, please see recent studies about Vitamin D that may reduce dangerous complications in diabetes and results showing plant-based protein foods may help reverse type 2 diabetes.
The research findings can be found in Ophthalmology Retina.
Copyright © 2026 Knowridge Science Report. All rights reserved.
